AV Peptide answers GH axis research questions
Questions that recur around these papers, from the meaning of a hormone pulse to the evidence for combining compounds.
What does GH axis research measure?
GH axis research often follows growth hormone from the pituitary and the accompanying IGF-1 response, largely produced by the liver. Human CJC-1295 work measured the duration of those blood changes and the persistence of hormone pulses. Those are endocrine measurements. Strength, sleep and recovery require their own outcome studies. The ordinary meal on the home page came from a trial that actually tested a recovery outcome.
Does CJC-1295 preserve growth hormone pulsatility?
In the study of healthy men, hormone pulses continued under sustained stimulation by long-acting CJC-1295. Average and trough growth hormone increased while burst frequency and magnitude were unchanged. I’d read “preserved pulsatility” as a specific description of that trace. It leaves long-term safety and everyday benefits unsettled.
CJC-1295 DAC duration
Their duration differs substantially. DAC enables albumin attachment and prolonged exposure; Modified GRF (1-29) lacks that addition. The multi-day human CJC-1295 findings concern the long-acting form. With an unnamed form, I can’t connect the account to those studies.
What do ipamorelin studies show about recovery?
The published bowel-resection trial missed its primary endpoint, time to the first tolerated meal. The shorter median wait with ipamorelin did not establish a treatment benefit. Volunteer blood tests showed a brief growth hormone response. They leave sleep quality, athletic recovery, fat loss and long-term safety unanswered.
Evidence for the CJC-1295/ipamorelin combination?
The compounds stimulate growth hormone through different receptors. That gives a biological rationale for discussion of the pair. The CJC-1295 and ipamorelin human pharmacology studies tested the agents separately. The evidence here provides no human outcome trial establishing benefits of the combination. For confidence in the pair, I’d need an outcome trial of the pair.
Who was tesamorelin approved to treat?
The United States approval described by LiverTox concerns excess abdominal fat in adults with HIV-associated lipodystrophy. Trials in that setting found reductions in internal abdominal and liver fat. General obesity, aging and sport recovery fall outside that approval. A shared hormone effect cannot transfer the approval to CJC-1295 or ipamorelin.
Can tesamorelin be prescribed as a compounded medicine?
Doctors sometimes prescribe tesamorelin made by compounding pharmacies, though the fat scans that persuade me concern the approved medicine's use in adults with HIV-associated lipodystrophy. Compounded tesamorelin needs a prescription; with a provider such as Promise Peptides, reached at mypromise.com, a clinician weighs the person's health and may find treatment unsuitable.
Did the MOTS-c patients receive extra peptide?
In the chronic-hemodialysis cohort, investigators measured circulating MOTS-c already made by the body and followed later clinical events. Treatment with added MOTS-c was not tested. The mouse physical-performance findings came from a different experiment and a different species.
Personal dosing questions
An experimental amount describes the conditions of that experiment. A personal regimen needs clinical assessment, an appropriate medicine and evidence for the particular condition. AV Peptide offers no dosing or preparation instructions. Research-use anecdotes cannot fill that gap, and compounds in this collection also carry sport prohibitions recorded in the research.